Results 1 to 10 of about 31,601 (273)
Patterns of Tumor Necrosis Factor Inhibitor (TNFi) Biosimilar Use Across United States Rheumatology Practices. [PDF]
ACR Open Rheumatology, 2020 ObjectiveIt is unclear if biosimilars of biologics for inflammatory arthritis are realizing their promise to increase competition and improve accessibility.
Bansback, Nick +8 more
core +2 more sources
Exploring Stakeholder Perceptions and Experience of Biosimilar Insulin Switching: A Scoping Review. [PDF]
Endocrinol Diabetes MetabThis scoping review has systematically mapped the existing literature on stakeholder perceptions and experience of biosimilar insulin switches. It shows that there is a lack of high‐quality context‐specific research in this area, and more needs to be done to understand this topic. ABSTRACT Background The option to switch patients to more cost‐effective
Hindley B +4 more
europepmc +2 more sources
Journal of the European Academy of Dermatology and Venereology, 2018 Linked article: This is a commentary on P. Yamauchi et al., pp. 1066–1074 in this issue.
Sandeep, Parsad, Chadi, Nabhan
+13 more sources
Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort [PDF]
Journal of Crohn's and Colitis, 2016 Background and Aims: Biosimilar infliximab CT-P13 is approved for all indications of the originator product in Europe. Prospective data on its efficacy, safety, and immunogenicity in inflammatory bowel diseases are lacking.
Klaudia Farkas +2 more
exaly +5 more sources
Knowledge and Attitude of Aseer Region Pharmacists Toward Biosimilar Medicines: A Descriptive Study. [PDF]
Healthcare (Basel)Alqahtani S, Almanasef M.
europepmc +2 more sources
Lupus, 2020 Biological therapies have widened the therapeutic armamentarium for immune-mediated inflammatory diseases, providing in many cases a broad range of treatment options with different mechanisms of action. The widespread use of biological agents in systemic lupus erythematosus is currently limited to belimumab and rituximab, although results of promising
Christopher J Edwards +1 more
+6 more sources
Rheumatology International, 2014 Etanercept was the first tumour necrosis factor alpha antagonist approved in the USA for the treatment of rheumatoid arthritis, in 1998, and then for other diseases. With the etanercept patent set to expire in the EU in 2015, a number of etanercept copies have reached the production phase and are undergoing clinical trials, with the promise of being ...
Azevedo, Valderilio F. +4 more
openaire +2 more sources
Therapeutische Umschau, 2011 Die Bewertung von Biosimilars stellt eine Herausforderung für alle an der Zulassung und an der Arzneimittelauswahl Beteiligten im Gesundheitswesen dar. Bewertungskriterien sind wie bei allen Arzneimitteln Qualität, Wirksamkeit, Sicherheit/Verträglichkeit und Wirtschaftlichkeit.
openaire +6 more sources
The Future of Generic Biologics: Should the United States “Follow-On” the European Pathway? [PDF]
, 2008 The United States is embarking on a biotechnology drug revolution. In the last few decades, biotech drugs have saved millions of lives, and the market for these miracle cures continues to grow at an astronomical rate.
Kaldre, Ingrid
core +4 more sources
Forced Degradation Testing as Complementary Tool for Biosimilarity Assessment [PDF]
, 2019 Oxidation of monoclonal antibodies (mAbs) can impact their efficacy and may therefore represent critical quality attributes (CQA) that require evaluation.
Dyck, Yan Felix Karl +6 more
core +1 more source